1-alkenylimidazole derivatives

FIELD: chemistry.

SUBSTANCE: invention relates to 1-alkenylimidazole derivatives of general formula 1 , where R is vinyl, allenyl or isopropenyl, R1 is hydrogen or methyl, E is Zn (II) or Fe(III), An is chlorine or acetate, n equals 1, 2 or 4, except compounds where R is vinyl, R1 is hydrogen, E is Zn(II), An is chlorine or acetate and n equals 2.

EFFECT: compounds have antihypoxic properties for different types of hypoxia.

5 ex, 8 tbl

 

The invention relates to new compounds of the number of metal complexes derived from 1-alkanolamide possessing biological activity, in particular antihypoxic.

Embedded in medical practice antihypoxants not meet the needs of doctors because of low efficiency and narrow range of effective doses or inability to provide a therapeutic effect in hypoxia of different Genesis. Therefore, the search for new chemical compounds with large antihypoxic activity in the different types of hypoxia, is an actual problem of modern pharmacology.

Known zinc complexes derived from bis - 1-vinylimidazole and-ethylvinylacetate with antigipoksicski properties poisoning carbon monoxide (patents No. 2038079, No. 2115653), and cobalt as hemodilator (patent No. 2157813).

The purpose of the invention is a new metal complex compounds derived from 1-alkanolamide with valuable biological activity, in particular antihypoxic properties for different types of hypoxia.

This goal is achieved by the synthesis of new complexes with derivatives of 1-alkanolamide and study of their biological activity in experimental pharmacological research.

Below are examples of the synthesis of new derivatives of adnych 1-alkanolamide and the results of the study of their pharmacological activity.

Synthesis of complexes based on 1-vinyl-, 1-alltel - and 1-Isopropenyl-imidazoles

Example 1. Tetra(1-vinylimidazole)telesotalania (code F4). At room temperature under stirring to 50.0 g (0.52 mol) of 1-vinylimidazole gradually add 17,57 g (0,065 mol) of hydrate of iron chloride(III). Upon completion of the reaction from the reaction flask at a residual pressure of 10-20 mm Hg distilled azeotrope mixture of 1-vinylimidazole with water, separating the precipitated yellow-brown, dry. Get 33,37 g of Tetra(1-vinylimidazole)telesotalania (98,79%) complex with TPL 155-157°C. Found, %: C 44,61; N 4,88; N 28,77; Cl 20,14. C20H24N8Cl3Fe. Calculated, %: C 45,3; N 4,71; N 28,81; Cl 20,51.

The structural formula

Example 2. Bis(1-allenylidene)cindicates (code AL1). of 5.11 g (0,051 mol) of 1-allenylidene dissolved in 200 ml of a mixture of absolute ether and acetone (3:1). To the resulting solution was added at room temperature under stirring 4,69 g (0,025 mol) of zinc diacetate. After 2 hours, separating the formed white precipitate, wash it with ether, dried, get 8,18 g (85,83%) bis(1-allenylidene)cindicates with TPL 122-124°C. Found, %: C 48,17; N. Of 4.35; N 14,21; Zn 16,62 C16H18N8O4Zn. Calculated, %: C 48,56; N 4,55; N 14,16; Zn 16,54.

The structural formula

Example 3. (1-Alltel-5-Mei)zencd the acetate (cipher AL2). of 6.90 g (0,0575 mol) 1-alltel-5-methylimidazole dissolved in 350 ml of a mixture of absolute ether and acetone (3:2). To the resulting solution was added at room temperature under stirring 6,35 g (0,0351 mol) of zinc diacetate. After 3 hours, separating the formed white precipitate, wash it with ether, dried, get 13,45 g (77,12%) 1-alltel-5-Mei)zincdiacetate with TPL 123-124°C. Found, %: C 43,17; N 4,65; N 9,17; Zn 21,43. C11H14N2O4Zn. Calculated, %: C 43,59; N Equal To 4.97; N 9,23; Zn 21,55.

The structural formula

Example 4. (1-Isopropylimidazole)cindicates (code PL1). 5,70 g (0,052 mol) of 1-isopropylimidazole dissolved in 300 ml of a mixture of absolute ether and acetone (2:1). To the resulting solution was added at room temperature under stirring 9,54 g (0,052 mol) of zinc diacetate. After 24 hours, separating the formed white precipitate, wash it with ether, dried, get 14,27 g (92,72%) (1-isopropylimidazole)cindicates with TPL 124-125°C. Found, %: C 41,37; N A 4.53; N 9,42; Zn 22,27. C10H14N2O4Zn. Calculated, %: C 41,18; N 4,80; N Being 9.61; Zn Of 22.44.

The structural formula

Example 5. (1-Isopropenyl-2-Mei)cindicates (code PL2). 3.00 g (0,0246 mol) 1-Isopropenyl-2-methylimidazole are dissolved in 140 ml of a mixture of absolute ether and acetone (3:1). To the resulting solution pribavlyayut room temperature with stirring to 4.52 g (0,0246 mol) of zinc diacetate. After 24 hours, separating the formed white precipitate, wash it with ether, dried, get 5,97 g (79,49%) (1-Isopropenyl-2-Mei)zincdiacetate with TPL 114-115°C. Found, %: C 43,28; N A 5.25; N 9,31; Zn 21,63. C11H16N2O4Zn. Calculated, %: C 43,22; N 5,24; N 9,17; Zn 21,41.

Study of the biological activity of derivatives of vinylimidazole

The study was conducted in accordance with article 11 Declaration of Helsinki of the world medical Association (1964), International recommendations for conducting biomedical research with animals (1985) and good laboratory practice in the Russian Federation (order of the Ministry of the Russian Federation No. 267 from 19.06.2003).

Research methodology

The experiment was performed at 260 outbred mice-males weighing 20-23 g using adequate methods of experimental acute hypoxia [1]. In mice caused acute hypobaric hypoxia (AGBG), acute histotoxic hypoxia (AGTG) introduction under the skin of the back of sodium nitroprusside (200 mg/kg). Experimental mice 1 hour prior to acute hypoxia was administered intraperitoneally in doses of 5-200 mg/kg of the compounds and the control animals in the same period and the same way with equal volume of distilled water. Antihypoxic action of the substances evaluated by the lifespan of mice in minutes.

Ciravegna experiments were processed statistically using the t student test [2].

The results of the study

It is established that the investigated metal-complex compounds vinylimidazole derivatives have antihypoxic activity, the severity of which depends on the compound, dose and models of hypoxia (table 1).

Most antihypoxic effect in 4 models of hypoxia showed azizol. Protective effect of alzola seen in Ohshc 6 doses, AGBG and AGTG - 5 doses, Ageg - in 3 doses. Antihypoxic action of the compounds according to the invention Tetra(1-vinylimidazole)relettered (F4) was statistically significant at OGTG in 3 doses, AGBG and Ohshc - in 2 doses, Ageg - 1 dose. Kobazol had antihypoxic effect when AGBG in 5 doses, when AGTG - 3 doses, when Ohshc and Ageg - 1 dose. The severity of antihypoxic action was more of alzola when AGBG, followed by the WHOLESALE, Oleg and Ohshc. Under the influence F4 most pronounced antihypoxic effect was when AGBG compared to OGTG, Ohshc and Oleg. Kobazol compared with etizolam and F4 showed a more pronounced antihypoxic action AGBG than AGTH and especially Oleg and Ohshc.

Drug comparison tool had a different impact on the lifespan of mice depending on the model, hypoxia, drug and dose. Antihypoxic action of neoglacial seen in Ohshc in 3 doses, AGBG, og and AGTG - in 2 doses. Lipoxen had a protective effect when AGBG in 3 doses, and when Ohshc, Oleg and AGTG - in 2 doses.

Thus, the metal complex compound F4 is of low toxicity (table 8) compared with other drugs, has a pronounced antihypoxic activity in models of acute hypoxia and may be recommended for further study as a possible drug that increases the body's resistance to acute hypoxia of different Genesis.

Study of the biological activity of derivatives alltel and isopropylimidazole

Research methodology

The experiments were conducted at 2100 outbred mice-males weighing 20-23, Used adequate methods of experimental acute hypoxia [1]. In mice caused acute hypobaric hypoxia (AGBG) "recovery" with a speed of 50 m/s at a height of 10000 m above sea level in the chamber Vita, acute hypoxia with hypercapnia (Ohshc) - placing each mouse in a transparent glass vessel with a capacity of 250 ml, acute gemicescuu hypoxia (Ageg) - introduction into the skin of the back of sodium nitrite (400 mg/kg), acute histotoxic hypoxia (AGTG) - introduction into the skin of the back of sodium nitroprusside (200 mg/kg). Experimental mice 1 hour prior to acute hypoxia was administered intraperitoneally in doses of 5-200 mg/kg of the compounds and the control animals in the t the t the same time and in the same way an equal volume of distilled water. Antihypoxic action of the substances evaluated by the lifespan of mice in minutes. The oxygen consumption of laboratory animals was determined using the apparatus of the closed type in the modification of Mitropolskogo (IV Sanotski, 1970) within 10 minutes after a 10-minute adaptation in the working chamber. The results of the measurements was calculated in ml per 1 minute per 100 g of body weight. Body temperature was measured electric thermometer in the rectum (O.N. Elizarova, 1974). Parameters of acute toxicity was determined by the method of Litchfield-Suggested by M. Belenky, 1963).

The results of the study

It is established that the magnitude and severity of antihypoxic effects depend on the compound, dose and models of hypoxia.

In terms of Ageg the lifespan of mice raised all four of the investigated derivatives alltel and isopropylimidazole (table 2). More pronounced antihypoxic effect as the breadth of the effective dose and the severity of the effect exerted connection under the code of AL2. So, AL2 three doses of 10, 25 and 50 mg/kg increased the lifetime of the animals, respectively, at 49, 63 and 42%. The connection under the code of AL1 at doses of 50 and 100 mg/kg increased the lifetime of the mice at 27 and 36%, PL1 at doses of 50 and 100 mg/kg - 82 and 42%; PL2 at doses of 50 and 100 mg/kg - 66 and 36%, respectively.

Model Ohshc increased the lifetime of the mice three of the four connect the deposits: AL1, AL2 and PL2 (table 3). The severity of antihypoxic action and breadth of effective doses was more complex compounds alle-elimidate under the code of AL1. So, AL1 four doses of 10, 25, 50 and 100 mg/kg, increased the lifespan of mice, respectively, at 23, 79, 94 and 91%. AL2 also increased the lifespan of mice in four doses of 25, 50, 100 and 150 mg/kg, respectively, at 24, 96, 95 and 70%. The connection under the code PL2 showed antihypoxic effect in three doses (25, 50 and 100 mg/kg), increasing the lifetime of the animals, respectively, at 25, 54 and 88%. Drug comparison lipoxen had antihypoxic effect, increasing the life span of mice by 20-33%and 27%.

Antihypoxic effect AGBG showed all four compounds that in three doses increased the lifetime of mice 269, 197, 169, 255% (table 4). Among the studied drugs comparison pronounced antihypoxic effect exerted lipoxen, increasing the life span of experimental mice at doses of 50, 100 and 150 mg/kg 144, 151 and 166%.

In terms OGTG the lifespan of mice raised all four of the investigated derivatives alltel and isopropylimidazole (table 5). Most active on the severity of the effect was the combination of a cipher PL1, which increased the lifetime of mice with three doses of 10, 25 and 50 mg/is g 55, 76% and 48% respectively. AL1 three doses of 25, 50 and 100 mg/kg increased the lifetime of the animals, respectively, 35, 56, and 24%. AL2 in doses of 25, 50 and 100 mg/kg, 20, 57, and 63%. PL2 doses of 10, 25 and 50 mg/kg, 45, 63 and 27%. Among the drugs comparison pronounced antihypoxic effect exerted lipoxen, increasing the lifetime of animals at doses of 50 and 100 mg/kg, respectively, 40 and 94%.

All investigated compounds was significantly reduced oxygen consumption and body temperature (table 6, 7), which also testify to their antihypoxic activity.

Parameters of acute toxicity are shown in table 8. The lowest toxicity has Tetra(1-vinylimidazole)telesotalania - determination of toxicity was suspended after intraperitoneal injection at a dose of 1 g/kg of body weight.

Thus, the results of our experiments allow to conclude that the newly synthesized metal complexes of derivatives of vinyl, alltel and isopropylimidazole are low-toxic and caused pronounced protective effect on the four models of acute hypoxia. Antihypoxic effect of these compounds on the latitude of the effective dose and the severity significantly exceeds that of the known antihypoxic drug lipoxen.

Sources of information

1. Lukyanova L.D. Methodological guidelines for experimental study of drugs, pre is assigned to a clinical study as a antihypoxic funds. - M., 1990. - 18 S.

2. Samoilov NN. Table of values for the mean error and credible interval arithmetic average value of the variation range. - Tomsk, 1970. - 63 S.

Table 1
Comparative antihypoxic activity of new metal-complex compounds derived vinylimidazole and antihypoxants at different models of hypoxia in relation to the control, taken as 100%
Cipher chemical compoundDose, mg/kgModel of hypoxia
AGBGOhshcAgegOGTG
123456
Derivatives of vinylimidazole
Azizol598±1393±7-114±4*
10216±4* 119±3*-143±7*
25374±6*139±8*104±6172±8*
50305±13*153±5*179±3*224±9*
100137±6*157±4*174±3*126±3*
150126±7*157±4*149±7*107±7
200106±11156±4*104±3-
F410---103±8
25106±3113±6113±3127±7*
50377±5*128±8*133±5*
100364±8*135±4*111±6115±4*
15095±12111±7-94±7
Kobazol5118±5*88±5--
10138±6*115±2*-96±6
25158±2116±5100±7130±5*
50230±8*-142±5*174±8*
100268±9*-94±7133±4*
150124±15*--
200101±12---
Nooglutil25104±9119±5*99±12104±5
50144±10*128±6*118±4*113±7*
100139±7*133±7*119±3*129±5*
Lipoxen25110±18--101±8
50224±9*--140±6*
100251±7*99±2111±2*194±7*
150266±8*133±2*119±2* 115±9
200123±18128±6*110±6-
(*)P<0.05 compared to control.

Table 2
Comparative impact of new metal-complex compounds derived alltel and propylimidazol and drug comparisons on the lifespan of mice in acute himicheskoi hypoxia compared with control taken as 100% (n=10)
№ p/pCipher chemical compoundDose, mg/kg
0,515102550100150200
1AL199±9101±2 120±6*127±7*136±5*92±3
2AL2106±3149±3*163±4*148±4*99±2-
3AP1-107±2123±7*182±3*142±4*97±3
4AR98±3136±3*166±5*169±4*136±7-
5Lipoxen 111±2*119±2*110±6
1. The asterisk (*) denotes significant differences (P<0.05) as compared to control.
2. Sign (-) marked not used in the experiments dose.

Table 3
Comparative impact of new metal-complex compounds derived alltel and propylimidazol and drug comparisons on the lifespan of mice under conditions of acute hypoxia with hypercapnia compared with control taken as 100% (n=10)
№ p/pCipher chemical compoundDose, mg/kg
15102550100150200
1AL1- 105±4123±4*179±23*194±10*191±7*-
2AL2--110±7124±9*196±13*195±10*170±7*-
3AP1-107±8110±7100±6----
4AR--100±5125±2*154±7*188±7*194±3*-
5Lipoxen----99±2 120±7133±2*127±5*
1. The asterisk (*) denotes significant differences (P<0.05) as compared to control.
2. Sign (-) marked not used in the experiments dose.

Table 4
Comparative impact of new metal-complex compounds derived alltel and propylimidazol and drug comparisons on the lifespan of mice in acute hypobaric hypoxia compared with control taken as 100% (n=10)
№ p/pCipher chemical compoundDose, mg/kg
0,515102550100150200
1AL1 117±7319±4*369±2*279±10*107±3-
2AL298±4143±3*167±8*191±14*297±12*117±14
3AP194±13123±3*127±6*323±2*269±5*134±10*97±10
4AR103±5142±6*219±11*310±8*355±8*274±15*228±7*109±2
5Lipoxen 110±18244±9251±7*266±8*123±18
1. The asterisk (*) denotes significant differences (P<0.05) as compared to control.
2. Sign (-) marked not used in the experiments dose.

Table 5
Comparative impact of new metal-complex compounds derived alltel and propylimidazol and drug comparisons on the lifespan of mice in acute gistologicheskoe hypoxia compared with control taken as 100% (n=10)
№ p/pCipher chemical compoundDose, mg/kg
0,515102550100150200
1AL1---118±4*135±3*156±3*124±5*105±9-
2AL2---105±3120±7*157±4*163±4*114±5-
3AP1101±4118±4*123±4*155±2*176±2*148±1*---
4AR117±4*139±4*145±5*163±3*127±2*110±6-- -
5Lipoxen-101±5140±3*194±2*115±8-
1. The asterisk (*) denotes significant differences (P<0.05) as compared to control.
2. Sign (-) marked not used in the experiments dose.

69±4*
Table 6
The oxygen consumption of the mice with intraperitoneal injection of new metal-complex compounds, derivatives of imidazole
№ p/pCipher chemical compoundDose, mg/kgOxygen consumption, %
SourceAfter 1 hourAfter 3 hoursAfter 6 hoursAfter 24 hours
1AL1 5010068±4*64±4*70±8*95±3
2AL25010076±3*73±4*81±7*99±3
3AP15010063±4*65±4*73±3*94±2
4AP25010073±4*66±4*77±3*96±3
5F45010088±5*86±4*104±391±4
6Kobazol5010068±5*82±8*96±3
7Azizol5010059±5*63±4*56±5*98±3
The asterisk (*) denotes significant differences (P<0.05) as compared with the initial value.

Table 7
The rectal temperature of mice with intraperitoneal injection of new metal-complex compounds, derivatives of imidazole
№ p/pCipher chemical compoundDose, mg/kgRectal temperature, %
SourceAfter 1 hourAfter 3 hoursAfter 6 hoursAfter 24 hours
1AL15010095±0,7*90±0,7*97±,7* 99±1
2AL25010095±0,7*77±2*96±0,7*96±1
3AP15010095±1*89±1*91±1*99±1
4AP25010094±1*89±1*95±0,7*101±0,6
5F45010096±0,6*95±1*97±198±1
6Kobazol5010088±1*92±1*93±1*98±0,6
7Azizol 5010090±0,7*89±0,2*94±1*99±1
The asterisk (*) denotes significant differences (P<0.05) as compared with the initial value.

Table 8
Acute toxicity of new metal-complex compounds, derivatives of imidazole intraperitoneal injection to mice
№ p/pCipher chemical compoundToxicity, mg/kg
LD16LD50LD84
1AL1105130165
2AL2165200245
3AP192,5105115
4AP2100190325
5F4More than 1000 mg/kg--

Derivatives of 1-alkanolamide General formula 1

where R is vinyl, alltel or Isopropenyl,
R1is hydrogen or methyl,
E - Zn(II) or Fe(III),
'an, chloride or acetate,
n is 1, 2 or 4
except for compounds,the
where R is vinyl, R1is hydrogen, e - Zn(II), An - chlorine or acetate, n - 2.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to zinc bis[2-(tosylamino)benzylidene-N-alkyliminates] of general formula , where Ts = tosyl, R=C7-C18 alkyl.

EFFECT: compounds exhibit luminescent properties and can be used as luminophors for making white and visible light organic light-emitting diodes.

3 cl, 2 ex

FIELD: physics.

SUBSTANCE: electroluminescent material is described, consisting of an electron injection layer, an active luminescent layer based on a metal chalate complex, a hole transport layer and a hole injection layer. The luminescent substance is in form of new zinc complexes based on sulphonylamino derivatives of 2-phenylbenzoxazole or 2-phenylbenzothiazole. The hole transport layer of the material is preferably a mixture of triphenylamine oligomers.

EFFECT: electroluminescent material with high moisture resistance, high resistance to crystallisation and high thermal stability.

9 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention concerns novel compound of zinc mezzo-triphenyltetra-[-(п-triphenylmethylphenoxybenzo)]monoazaporphyrinate.

EFFECT: possible application as fat-soluble green colourant for polymers, as material for thin film microelectronics, as catalyst, and in other scientific and technical fields.

1 cl, 1 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to obtaining etyheleneammonium bis(1-hydroxyethane-1,1-diphosphonato(2-))cuprate (+2), etyheleneammonium bis(1-hydroxyethane-1,1-diphosphonato(2-)) zincate(+2) and etyheleneammonium bis(1-hydroxyethane-1,1-diphosphonato(2-)) nickelate(+2) and can be used for processing toxic wastes of obtaining metal coatings - waste electrolytes of galvanic copper, zinc and nickel plating, waste solutions of chemical nickel plating and copper plating. Products, obtained by said method, can be used for preparation of electrolytes, metal corrosion inhibitors, for obtaining various copper, zinc and nickel compounds, including catalysts of organic and inorganic substance synthesis. Claimed method includes using liquid industrial wastes, containing metal(+2), ethyleneammonium and/or anion of 1-hydroxyethane-1,1-diphosphonic acid as reagents. Target products are obtained by crystallisation from reaction water solution with separation of sediment from solution, process is carried out at temperature from (-5) to 105°C and atmospheric pressure. Method allows to obtain pure crystalline products with yield up to 98%, to reduce expenditures on environment protection.

EFFECT: method simplification and increase of its manufacturability.

7 cl, 9 ex

FIELD: chemistry.

SUBSTANCE: as photosensibilizers emulsions of alkylthiosubstituted phalocyanides of general formula , where R1=R4=Cl, R2=R3=n-C10H21S, M=Zn or R1=t-C4H9S, R2=R3=R4=H, M=HH or R1=t-C4H9S, R2=R4=H, R3=t-C4H9, M=HH or R1=R3=t-C4H9S, R2=R4=H, M=HH or R1=R2=R3=R4=t-C4H9S, M=HH or R1=R4=Cl, R2=R3=t-C4H9S, M=Zn, in water solution of Proxanol 268 are suggested.

EFFECT: elaboration of highly selective and efficient photosensibilizers for application in photodynamic therapy of tumours.

3 cl, 18 ex, 4 tbl, 9 dwg

FIELD: chemistry.

SUBSTANCE: invention concerns a new compound, zinc meso-trans-dihexadecyltetrabenzoporphyrinate .

EFFECT: compound can be applied as a fat-soluble green colorant for solution dyeing of paraffin and polyethylene.

1 cl, 2 ex, 2 dwg

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention proposes an improved method for synthesis of bis-(1-vinylimidazole)-zinc diacetate representing a complex compound of zinc diacetate with 1-vinylimidazole and known as medicinal preparation acizol. Acizol is an effective antidote and antihypoxic agent of the broad spectrum of effect. Method for synthesis of 1-vinylimidazole metal with zinc diacetate of the composition 2:1 involves carrying reaction in the absence of solvent and using available commercial zinc diacetate of the formula Zn(OCOCH3)2 x 2 H2O in the stoichiometric mole ratio 1-vinylimidazole : salt in the range from 2.9:1 to 2:1, and synthesized pure product is isolated by water distilling off or its azeotropic mixture with 1-vinylimidazole. Method provides excluding the dehydration step of parent zinc salt from technological process and to decrease consumption of used reagent 1-vinylimidazole significantly, Invention provides significant reducing energetic and industrial consumptions, simplifying and decreasing cost of process and retaining the quantitative yield of highly pure pharmacopoeia acizol preparation.

EFFECT: improved method of synthesis.

4 ex

FIELD: luminescent substances, organic chemistry.

SUBSTANCE: invention relates to electroluminescent materials containing organic luminescent substance. Invention describes novel electroluminescent material consisting of injection layer, active luminescent layer based on chelate metal complex, hole-transporting layer and hole-injecting layer. Material comprises metal complexes based on sulfanyl derivatives of 8-aminoquinoline as a luminescent substance, in particular, zinc complexes of 8-(methylsulfanylamino)-quinoline and 8-(3,5-difluorophenylsulfanylamino)-quinoline. Material comprises a mixture of triphenylamine oligomers as a hole-transporting layer. Invention provides creature of electroluminescent material showing the enhanced moisture resistance, enhanced resistance to crystallization and enhanced thermal stability.

EFFECT: improved and valuable properties of material.

4 cl, 5 ex

FIELD: organic chemistry.

SUBSTANCE: invention relates to novel compounds, namely zinc bis-[2-(tosylamino)benzylidene-N-alkyl(aryl, hetaryl)aminates] of the general formula (I): wherein Ts means tosyl; R means (C1-C6)-alkyl with exception isopropyl, (C1-C6)-alkyl-substituted phenyl, (C1-C6)-alkoxy-substituted phenyl with exception para- and ortho-methoxyphenyl, pyridyl, (C1-C6)-alkylpyridyl, or R + R form in common disulfidodialkyl group -(CH2)n-S-S-(CH2)n- wherein n = 1-3, but preferably to zinc bis-[2-(tosylamino)benzylidene-N-alkylidenemercaptoaminates] of the general formula (Ia): Compounds can be used for synthesis of light-radiating organic diode of white and visible light. Fluorescence can be observed in blue region of spectrum with fluorescence bands maximum at 428-496 nm. Quantum yields are 0.2-0.25.

EFFECT: valuable physical properties of compounds.

5 cl, 8 ex

FIELD: medicine, in particular photosensitizing agents for antimicrobial photodynamic therapy.

SUBSTANCE: invention relates to new photosensitizing agents for antimicrobial photodynamic therapy namely cationic phthalocyanines of general formula MPc(CH2X)nCln, wherein Pc is phthalocyanine rest C32H16N8; M is Zn, AlY; n = 6-8; X is Y is Cl, OH, OSO3H. Claimed agents is characterized by wide range of antimicrobial activity. Single complex action of nontoxic in darkness micromolar (up to 2.0 muM) concentration thereof and low dose of red irradiation make it possible to produce high inactivation levels (up to 97-99 %) both gram-negative bacteria and yeast fungi of genus Candida.

EFFECT: improved agents for treatment of various severe complications of inflammation diseases.

3 dwg, 13 ex, 2 tbl

FIELD: process engineering.

SUBSTANCE: invention relates to complete methane oxidation catalysts and can be used in industries using diesel fuel. Invention covers complete methane oxidation catalysts based on strontium hexaferrites of the following composition: SrMnxFe12-xO19, where x=0, 1, 2, 6. Proposed method comprises settling catalyst components with the help of NH4HCO3 solution at constant pH equal to (7.1 to 8.0) and temperature not lower than 70°C with subsequent stages of filtration, rinsing, drying and roasting. Proposed method comprises also the stage of heat treatment at 800° to 1000° C and is realised in the presence of above described catalysts.

EFFECT: high degree of methane conversion at relatively low temperatures.

6 cl, 2 tbl, 14 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a polyolefin synthesis method and more specifically to a polyethylene synthesis method. Polyethylene is a copolymer of ethylene with 1-alkenes. The invention also relates to polyethylene synthesis catalyst systems. The catalyst system is a mixture of metallocenes: hafnocene and an iron-based complex, an activating compound and a support. The invention also relates to films made from polyethylene and packets made from the said films.

EFFECT: disclosed catalyst system enables production of polyethylene with given molecular weight distribution in a single reactor.

16 cl, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing iron (II) oxalate by directly reacting metal with acid in the presence of atmospheric oxygen and a liquid phase while stirring. The process is carried out in a bead mill. The liquid phase solvent used is water with mass ratio of the liquid phase to glass beads equal to 1:1, content of oxalic acid in the initial load is between 0.5 and 2.0 mol/kg, and content of stimulating sodium chloride additive is between 0.02 and 0.10 mol/kg. Crushed grey cast iron which is stirred by a blade mixer is taken in amount of 30% of the mass of the rest of the load. The process is started and carried out at temperature in the interval from (50±2) to (93±2)°C while bubbling air under conditions for stabilising temperature using a heated liquid bath and controlling using a sample taking method and determination of content of iron (II) and (III) salts in the samples, and residual quantity of acid up to virtually complete conversion of the latter into salt. After that air bubbling, external heat supply for stabilising temperature and stirring are stopped. The suspension of the reaction mixture is separated from the glass beads and particles of unreacted metal alloy and filtered. The filtration residue is washed with distilled water and taken for further purification through recrystallisation, while the filtrate and the washing water are returned to the load for the repeated process. Iron (II) oxalate, which is separated from the reaction mixture by traditional filtering, is virtually the only product of conversion.

EFFECT: liquid phase used together with the sodium chloride additive can be repeatedly returned to the process.

10 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: iron (II) fumarate can be used in different fields of chemical practice, in analytical control and in scientific research, through direct reaction of iron with fumaric acid in the presence of a catalyst, where the catalyst used is molecular iodine in amount of 0.025 to 0.1 mol/kg of the initial load, iron is taken in large excess in form of shells on the entire height of the reactor, false bottom and blade mixer, as well as in form of crushed cast iron and(or) reduced iron powder, the liquid phase solvent used is butylacetate, in which iodine and fumaric acid are at least partially dissolved, where fumaric acid is taken in amount of 0.8 to 1.2 mol/kg of the initial load, loading is done in the sequence: glass beads, liquid phase solvent, fumaric acid, iodine, and then crushed cast iron and(or) reduced iron powder; the process is started at room temperature and is carried out in a vertical type bead mill with ratio of mass of beads to mass of crushed cast iron and(or) reduced iron powder equal to 4:1, at temperature ranging from 18 to 45°C while bubbling air with flow rate of 0.95 l/min-kg of the liquid phase and using forced cooling and controlling using a sampling method until complete exhaustion of the loaded acid for formation of salt, after which stirring and cooling are stopped, the reaction mixture is separated from glass beads and unreacted crushed cast iron and(or) reduced iron powder and filtered, the residue is washed with butylacetate and taken for recrystallisation, and the filtrate and washing butylacetate are returned to the repeated process. Amount of acid used in extracting the product (without loss during purification) ranges from 89 to 96.5%, which depends on conditions for carrying out the process.

EFFECT: improved method of producing said product.

8 ex

FIELD: chemistry.

SUBSTANCE: invention refers to coordination chemistry: specifically, to improved method of producing heterometal neodymium (III) and iron (III) malate of formula 1 to be used for synthesis of mixed oxides of perovskite composition. . Method is enabled by electrolysis of concentrated aqueous solution of neodymium (III) nitrate and malic acid in ratio 1:3 with pyridine or lithium perchlorate with anode added, pressed from recovered iron, and inert cathode from graphite with using pulse current of variable porosity. Thereafter the solution is evaporated with precipitation then washed with ethanol and dried.

EFFECT: method is cost-effective, controlled and productive.

3 cl, 3 tbl, 1 dwg

FIELD: chemistry.

SUBSTANCE: as catalyst substituted iron phthalocyanines of general formula ,

where R=[CH2N+(CH3)2CH2CH2OH]Cl-, L=(CH3)2NCH2CH2OH (I);

R=[CH2N+(CH3)2CH2CH2N(CH3)2]Cl-, L=(CH3)2NCH2CH2N(CH3)2 (III);

are used. Oxychlorination is carried out with mixture of H2O2 and HCl in water-alcohol medium in presence of suggested catalyst.

EFFECT: simplification of technology of obtaining chlor-derivatives of aromatic hydrocarbons with good yield and quality of product.

2 cl, 19 ex

FIELD: chemistry.

SUBSTANCE: invention concerns improved method of obtaining mevalonic acid derivatives of the general formula I or its pharmaceutically acceptable salt with base, or lactone, where -CH2-CH2- or -CH=CH-, R is heterocyclical residual of interaction of compound of the general formula IIa , where R1, R2, R3, R4 meanings are described in the invention, with compound of the general formula IIb: R-CH(=O) where R is cyclical residual. Obtained compound is recovered in the presence of recovery agent, preferably a compound of the formula IId , where M is Ru, Rh, Ir, Fe, Co, Ni, L1 - H, L2 - aryl, R5 is aliphatic residual, R8 and R9 are C6H5 or form cyclohexane ring or cyclohexane or cyclopentane ring combined with C atom, to which they are bound, with a number of further stages.

EFFECT: high product output.

4 cl, 1 ex

FIELD: salts of iron and organic acid producing processes, namely production of salt of iron (III) and acetic acid.

SUBSTANCE: method is realized by relation of metallic iron with acetic acid at presence of oxidizing agent; using molecular iodine, iron oxides such as Fe2O3, Fe3O4 and oxygen of air as oxidizing agent for converting impurity of iron (II) acetate to basic iron (III) acetate. Process is performed in beads mill at temperature 80°Cand at mass relation of liquid charge and glass beads 1 : 1. Iron is used in the form of shell abutted to lateral surface of reactor housing. Initial molar relation of iron oxide and iodine is 10 : 1. Molar relation of acetic acid, its anhydride and iron oxide is in range 100 : (2 - 5.99) : (2 - 2.5). In time moment of practically complete consumption of iron oxide, solid phase of reaction mixture is taken off by filtering. Simultaneously consumed reagents are replenished and filtrate is returned to reactor for repeating process. Number of processes to be repeated is no more than 5. At second stage residues of iron (II) salt are after-oxidized to basic iron (III) acetate due to drying up taken off solid phase of product in filter by means of blowing air at environmental temperature. Preferably, hematite, γ-oxide or minimum is used as Fe2 O 3 and magnetite and Fe3O4 x 4H2Ois used asFe3 O4.

EFFECT: simplified process, usage of available reagents.

3 cl, 9 notes, 2 tbl

FIELD: coordination compound chemistry.

SUBSTANCE: invention relates to technology of complexes of iron with salicylic acid suitable for use in a variety of technical areas and in medicine. Title complex is obtained via interaction of metal with acid using air oxygen as oxidant. Salicylic acid is used in butyl acetate or n-butyl alcohol solution with dissolved molecular iodine or potassium iodide. Iron is provided in the form of steel or cast iron shell, shaft, and blade of mechanical mixer as well as, agitated by the mixer, reduced iron powder fractions, broken cast iron or broken steel cuttings, cast iron or steel filings. Process is carried out at stirring with high-speed mechanical stirrer and air bubbling allowing self-heating of reaction mixture to 70-80°C until 1.72-1.85 mole/kg iron compounds is accumulated in reaction mixture in the form of suspension, whereupon mixing is stopped. Suspension is freed of unreacted fine iron and/or alloy(s) thereof and subjected to hot filtration, Filtrate is warmed to eliminate precipitated solid phase and then slowly cooled to ambient temperature. Precipitated solid phase is filtered off, dried, and recrystallized, while filtrate is recycled.

EFFECT: improved technology required only accessible starting materials and increased yield of desired product.

2 cl, 4 ex

FIELD: technology of production of iron and salicylic acid complexes used in various fields of engineering and medicine.

SUBSTANCE: proposed iron (III) complex with three anions of salicylic acid is produced due to interaction of iron and its alloys with salicylic acid dissolved in dimethyl formamide in vertical bead-type mill provided with high-speed mechanical blade-type agitator at bubbling of air and spontaneous heating of reaction mixture to 80-90C. Iron is presented in form of steel or cast-iron ferrule over entire height of bead-type mill, steel shaft and blade of mechanical agitator, as well as in form of iron powder, fraction of broken cast iron, broken steel chips or cast-iron shot. Process is completed at accumulation of iron salts in reaction mixture of 1.12-1.30 mole/kg; 95% of these salts are in target compounds of iron (III). Hot suspension is filtered immediately and filtrate is cooled down for crystallization of main mass of iron (III) complex. Precipitated product is filtered and is directed for re-crystallization, if necessary. Filtrate is returned for repeated process.

EFFECT: updated technology; high yield of product.

2 ex

FIELD: chemical industry, in particular two-component heterogeneous immobilized catalyst for ethylene polymerization.

SUBSTANCE: claimed catalyst includes alumina, mixture of transition metal complexes with nitrogen skeleton ligands (e.g., iron chloride bis-(imino)pyridil complex and nickel bromide bis-(imino)acetonaphthyl complex). According the first embodiment catalyst is prepared by application of homogeneous mixture of transition metal complexes onto substrate. iron chloride bis-(imino)pyridil complex and nickel bromide bis-(imino)acetonaphthyl complex (or vise versa) are alternately applied onto substrate. According the third embodiment catalyst is obtained by mixing of complexes individually applied onto substrate. Method for polyethylene producing by using catalyst of present invention also is disclosed.

EFFECT: catalyst for producing polyethylene with various molecular weights, including short chain branches, from single ethylene as starting material.

7 cl, 5 tbl, 27 ex

Up!